肠道菌群与肿瘤免疫治疗

Gut microbiome and tumor immunotherapy

免疫治疗在难治性肿瘤的临床实践中取得重大突破,但在临床应用中依然存在治疗结果的个体差异性和耐药性问题。肠道菌群是近年来逐渐受到重视的免疫调节因素,越来越多的研究关注到其对肿瘤免疫治疗效果的影响。以肠道菌群为靶点,提高肿瘤患者对免疫治疗的应答效果,具有潜在的临床应用价值。

Neoplasms immunotherapy has made a major breakthrough in the clinical practice of refractory tumor.However,there are still individual differences in treatment results and drug resistance in clinical application.Gastrointestinal microbiome is gradually recognized as an immunoregulatory factor in recent years,and more and more studies have focused on its influences on the efficacy of tumor immunotherapy.Targeting gastrointestinal microbiota to improve the response of tumor patients to immunotherapy has potential clinical application value.